Recent Updates — SMMT
On September 28, 2026, Summit Therapeutics Inc. entered into a securities purchase agreement with AstraZeneca Holdings B.V. for a $2 billion strategic equity investment. The company issued approximately 108,955 shares of newly designated Class A Convertible Preferred Stock at a price of $18,356.14 per share. Each preferred share is convertible into 1,000 shares of common stock, implying an effective common stock price of $18.36. The transaction includes a clinical trial collaboration to evaluate sonesitatug vedotin in combination with ivonescimab for gastrointestinal cancers and a non-binding memorandum of understanding to explore further combinations with AstraZeneca's oncology portfolio. Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of cancer therapies.
On September 15, 2026, Summit Therapeutics announced updated overall survival results from the global Phase III HARMONi clinical trial for ivonescimab presented at WCLC 2026. With a June 2026 data cut-off, the study showed an OS hazard ratio of 0.76 (nominal p=0.0151) in the global population and consistent results in Western patients, reinforcing efficacy trends observed previously. Median overall survival remained at 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo. The company also presented HARMONi-2 data from partner Akeso showing a significant OS benefit (HR 0.73) in China. Summit's BLA for ivonescimab has a PDUFA goal date of November 14, 2026. Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery and development of medicinal therapies.
Summit Therapeutics announced that partner Akeso will present updated overall survival data from the Phase III HARMONi-2 trial at the IASLC World Conference on Lung Cancer on September 15, 2026. The interim analysis showed ivonescimab reduced the risk of death by 27% compared to pembrolizumab (HR 0.73), with a median overall survival of 30.8 months versus 22.6 months. In PD-L1 high-expressing patients, the hazard ratio was 0.58. Summit is concurrently conducting the global Phase III HARMONi-7 study for ivonescimab in this patient population. The company operates in the biopharmaceutical oncology industry, focusing on the discovery and development of immunotherapy treatments.
On September 2, 2026, Summit Therapeutics announced that partner Akeso reported positive overall survival results from the Phase III HARMONi-2 study of ivonescimab in PD-L1-positive non-small cell lung cancer. Ivonescimab demonstrated a statistically significant improvement compared to pembrolizumab monotherapy, reinforcing its approval by China’s NMPA in April 2025. Summit continues global development with the HARMONi BLA for FDA acceptance and a PDUFA date of November 14, 2026. The company operates as a biopharmaceutical oncology firm focused on discovering and developing medicinal therapies.
On August 25, 2026, Summit Therapeutics announced that partner Akeso reported positive topline results from the Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy versus durvalumab plus chemotherapy for first-line advanced biliary tract cancer. The regimen achieved statistically significant and clinically meaningful superiority in overall survival, progression-free survival, and objective response rate. This marks the first known Phase III study in this indication to demonstrate overall survival benefit against an anti-PD-(L)1 plus chemotherapy backbone. Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies.
On August 5, 2026, Summit Therapeutics announced the expansion of its global clinical development program for ivonescimab into urothelial carcinoma (bladder cancer) with the planned initiation of the Phase II/III HARMONi-GU1 trial. This study will evaluate ivonescimab combined with enfortumab vedotin versus pembrolizumab plus enfortumab vedotin as first-line therapy for previously untreated locally advanced or metastatic disease, aiming to enroll approximately 800 patients through Phase III. Global site activations are scheduled to begin in the fourth quarter of 2026. This development adds to Summit's broader ivonescimab program, which includes multiple ongoing and completed Phase III trials across other tumor types such as non-small cell lung cancer and colorectal cancer. Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies for serious unmet medical needs.